Dravet Syndrome Therapeutics Market Size, Share and Forecast 2026
Dravet syndrome therapeutics market was worth the US $XX billion in 2018 and is expected to reach US $XX billion by 2026, at a CAGR of XX% during the forecast period.
(EMAILWIRE.COM, September 13, 2019 ) Market Overview:
Dravet syndrome is an epilepsy syndrome that begins in early childhood with a spectrum of symptoms ranging from mild to severe. It can occur due to mutations in SCN1A gene or from family. According to the National Center for Advancing Translational Sciences, it is reported that 85% of Dravet syndrome cases originated due to a mutation in the SCN1A gene and, 15% to 25% cases of the Dravet syndrome, a family history of epilepsy or febrile seizures exists.
Market Dynamics:
Many factors such as the rising R&D expenditure, increasing government assistance, rising healthcare expenditure in the developed countries, are the few factors propelling the growth of the global Dravet syndrome market. However, side effects of drugs and other therapeutic agents, lack of awareness among people are the major factors hampering the global Dravet syndrome therapeutics market.
Market Segmentation:
By Treatment Type
• Anticonvulsant therapies
• Cannabinoid-based therapies
• Vagus nerve stimulation (VNS)
Geographical Analysis:
By Geography, the market is segmented into:
• North America
• Europe
• South America
• Asia Pacific
• The Middle East and Africa
Competitive Analysis:
Key Players:
• Epygenix Therapeutics, Inc.*
• GW Pharmaceuticals Plc.
• Ovid Therapeutics
• Takeda Pharmaceutical Company Ltd
• OPKO Health Inc.
• Zogenix, Inc
• Others
View full report: https://www.datamintelligence.com/research-report/dravet-syndrome-therapeutics-market
Download free sample: https://www.datamintelligence.com/download-sample/dravet-syndrome-therapeutics-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Dravet syndrome is an epilepsy syndrome that begins in early childhood with a spectrum of symptoms ranging from mild to severe. It can occur due to mutations in SCN1A gene or from family. According to the National Center for Advancing Translational Sciences, it is reported that 85% of Dravet syndrome cases originated due to a mutation in the SCN1A gene and, 15% to 25% cases of the Dravet syndrome, a family history of epilepsy or febrile seizures exists.
Market Dynamics:
Many factors such as the rising R&D expenditure, increasing government assistance, rising healthcare expenditure in the developed countries, are the few factors propelling the growth of the global Dravet syndrome market. However, side effects of drugs and other therapeutic agents, lack of awareness among people are the major factors hampering the global Dravet syndrome therapeutics market.
Market Segmentation:
By Treatment Type
• Anticonvulsant therapies
• Cannabinoid-based therapies
• Vagus nerve stimulation (VNS)
Geographical Analysis:
By Geography, the market is segmented into:
• North America
• Europe
• South America
• Asia Pacific
• The Middle East and Africa
Competitive Analysis:
Key Players:
• Epygenix Therapeutics, Inc.*
• GW Pharmaceuticals Plc.
• Ovid Therapeutics
• Takeda Pharmaceutical Company Ltd
• OPKO Health Inc.
• Zogenix, Inc
• Others
View full report: https://www.datamintelligence.com/research-report/dravet-syndrome-therapeutics-market
Download free sample: https://www.datamintelligence.com/download-sample/dravet-syndrome-therapeutics-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results